Document Detail

Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.
MedLine Citation:
PMID:  12037229     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A study was undertaken to investigate whether bronchodilators are associated with less breathlessness at rest and during light exercise in patients with moderate to severe chronic obstructive pulmonary disease (COPD) with resting tidal expiratory flow limitation (EFL; flow limited (FL)) compared with those without EFL (non-flow limited (NFL)). METHODS: Twenty subjects (13 men) of mean (SD) age 65 (8) years (range 43-77) suffering from COPD with forced expiratory volume in 1 second (FEV(1)) 47 (18)% predicted were studied before and after inhalation of salbutamol (400 microg). Routine pulmonary function tests were performed in the seated position at rest. EFL was assessed by the negative expiratory pressure (NEP) method and changes in end expiratory lung volume (EELV) were inferred from variations in inspiratory capacity (IC). Dyspnoea was measured using the Borg scale at rest and at the end of a 6 minute steady state exercise test at 33% of the maximal predicted workload. RESULTS: EFL occurred in 11 patients. Following salbutamol IC did not change in NFL patients but increased by 24% (95% CI 15 to 33) in FL patients (p<0.001). Maximal inspiratory pressure (PImax) improved at EELV from 45 (95% CI 26 to 63) to 55 (95% CI 31 to 79) cm H(2)O (p<0.05) in FL patients after salbutamol but remained unchanged in NFL patients. The workload performed during exercise amounted to 34 (95% CI 27 to 41) and 31 (95% CI 21 to 40) watts (NS) for patients without and with EFL, respectively. After salbutamol, dyspnoea did not change either at rest or during exercise in the NFL patients, but decreased from 0.3 (95% CI -0.1 to 0.8) to 0.1 (95% CI -0.1 to 0.4) at rest (NS) and from 3.7 (95% CI 1.7 to 5.7) to 2.6 (95% CI 1.1 to 4.0) at the end of exercise (p<0.01) in FL patients. CONCLUSIONS: Patients with COPD with EFL may experience less breathlessness after a bronchodilator, at least during light exercise, than those without EFL. This beneficial effect, which is closely related to an increase in IC at rest, occurs even in the absence of a significant improvement in FEV(1) and is associated with a greater PImax.
E Boni; L Corda; D Franchini; P Chiroli; G P Damiani; L Pini; V Grassi; C Tantucci
Related Documents :
11069799 - Exercise-induced lactate increase in relation to muscle substrates in patients with chr...
17010529 - Exercise and the inflammatory response in chronic obstructive pulmonary disease (copd)-...
18550609 - Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in copd.
3513269 - Effects of beta-agonists on breathlessness and exercise tolerance in patients with chro...
10741769 - Nutrition in chronic obstructive pulmonary disease.
16584369 - Copdx: an update of guidelines for the management of chronic obstructive pulmonary dise...
3723069 - The role of catecholamines in erythrocyte ph regulation and oxygen transport in rainbow...
6836649 - Pathophysiology of ischemic cell death: iii. role of extracellular factors.
12039439 - Genomic plasticity, energy allocations, and the extended longevity phenotypes of drosop...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thorax     Volume:  57     ISSN:  0040-6376     ISO Abbreviation:  Thorax     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-30     Completed Date:  2002-07-16     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0417353     Medline TA:  Thorax     Country:  England    
Other Details:
Languages:  eng     Pagination:  528-32     Citation Subset:  IM    
Cattedra di Medicina I, Università di Brescia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Albuterol / therapeutic use*
Bronchodilator Agents / therapeutic use*
Chronic Disease
Dyspnea / etiology*,  physiopathology
Expiratory Reserve Volume / physiology
Forced Expiratory Flow Rates
Forced Expiratory Volume / physiology
Middle Aged
Pulmonary Disease, Chronic Obstructive / complications,  drug therapy*,  physiopathology
Vital Capacity / physiology
Reg. No./Substance:
0/Bronchodilator Agents; 18559-94-9/Albuterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with ...
Next Document:  Effect of CPAP on intrinsic PEEP, inspiratory effort, and lung volume in severe stable COPD.